Knowledge center

Back to overview
Whitepaper

Quality by Design (QbD) and detecting crystal polymorphs

Here, we look at the obstacles that have prevented the further development of XRPD in the pharmaceutical industry, and the trends in instrumentation that are now breaking these barriers.

X-ray powder diffraction (XRPD) has a long association with the pharmaceutical industry. For many years the technique has been essential for obtaining the data necessary for securing patents, registering new products and for demonstrating compliance with industry regulations. However, despite the great potential XRPD offers for numerous other pharmaceutical applications, until recently there has been a bottleneck to its expansion.

Download white paper
You'll need Adobe Acrobat to read this file. Download it here

Share this article